• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嵌合血凝素分裂疫苗在小鼠中诱导广泛交叉反应性抗体,并对 2 组流感病毒提供保护。

Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.

机构信息

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

出版信息

Sci Adv. 2023 Sep 15;9(37):eadi4753. doi: 10.1126/sciadv.adi4753. Epub 2023 Sep 13.

DOI:10.1126/sciadv.adi4753
PMID:37703367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10499326/
Abstract

Seasonal influenza virus vaccines are effective when they are well matched to circulating strains. Because of antigenic drift/change in the immunodominant hemagglutinin (HA) head domain, annual vaccine reformulations are necessary to maintain a match with circulating strains. In addition, seasonal vaccines provide little to no protection against newly emerging pandemic strains. Sequential vaccination with chimeric HA (cHA) constructs has been proven to direct the immune response toward the immunosubdominant but more conserved HA stalk domain. In this study, we show that immunization with group 2 cHA split vaccines in combination with the CpG 1018 adjuvant elicits broadly cross-reactive antibodies against all group 2 HAs, as well as systemic and local antigen-specific T cell responses. Antibodies elicited after sequential vaccination are directed to conserved regions of the HA such as the stalk and the trimer interface and also to the N2 neuraminidase (NA). Immunized mice were fully protected from challenge with a broad panel of influenza A viruses.

摘要

季节性流感病毒疫苗在与流行株匹配良好时才有效。由于免疫显性血凝素 (HA) 头部结构域的抗原漂移/变化,需要每年进行疫苗配方改革以保持与流行株的匹配。此外,季节性疫苗对新出现的大流行株几乎没有保护作用。嵌合 HA (cHA) 构建体的序贯疫苗接种已被证明可将免疫反应引导至免疫亚显性但更保守的 HA 茎域。在这项研究中,我们表明,用组 2 cHA 裂疫苗与 CpG 1018 佐剂联合免疫可引发针对所有组 2 HA 的广泛交叉反应性抗体,以及全身性和局部抗原特异性 T 细胞反应。序贯疫苗接种后产生的抗体针对 HA 的保守区域,如茎部和三聚体界面,以及 N2 神经氨酸酶 (NA)。免疫接种的小鼠完全免受广泛的流感 A 病毒的挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/2c64d2db5092/sciadv.adi4753-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/7e3fc1ee8cc9/sciadv.adi4753-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/c0da08090bdc/sciadv.adi4753-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/9ed72c13952d/sciadv.adi4753-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/f18920d2423f/sciadv.adi4753-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/2c64d2db5092/sciadv.adi4753-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/7e3fc1ee8cc9/sciadv.adi4753-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/c0da08090bdc/sciadv.adi4753-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/9ed72c13952d/sciadv.adi4753-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/f18920d2423f/sciadv.adi4753-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aae/10499326/2c64d2db5092/sciadv.adi4753-f5.jpg

相似文献

1
Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.嵌合血凝素分裂疫苗在小鼠中诱导广泛交叉反应性抗体,并对 2 组流感病毒提供保护。
Sci Adv. 2023 Sep 15;9(37):eadi4753. doi: 10.1126/sciadv.adi4753. Epub 2023 Sep 13.
2
Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes.具有乱序免疫优势表位的 H3 血凝素流感疫苗诱导针对免疫亚优势头部表位的抗体。
mBio. 2023 Aug 31;14(4):e0062223. doi: 10.1128/mbio.00622-23. Epub 2023 Jul 19.
3
Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.神经氨酸酶抑制抗体滴度与对同一神经氨酸酶亚型的异源流感病毒株的保护作用相关。
J Virol. 2018 Aug 16;92(17). doi: 10.1128/JVI.01006-18. Print 2018 Sep 1.
4
Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.基于活减嵌合血凝素疫苗的序贯免疫在临床前雪貂模型中诱导针对甲型流感病毒的异源型免疫。
Front Immunol. 2019 Apr 10;10:756. doi: 10.3389/fimmu.2019.00756. eCollection 2019.
5
Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.用水泡性口炎病毒载体嵌合血凝素疫苗接种可保护小鼠免受不同流感病毒攻击毒株的侵害。
J Virol. 2015 Dec 16;90(5):2544-50. doi: 10.1128/JVI.02598-15.
6
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.基于嵌合血凝素的流感病毒疫苗在小鼠中诱导保护性茎特异性体液免疫和细胞反应。
Immunohorizons. 2019 Apr 1;3(4):133-148. doi: 10.4049/immunohorizons.1900022.
7
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.接种表达神经氨酸酶的重组副流感病毒5可抵御同源和异源流感病毒攻击。
J Virol. 2017 Nov 14;91(23). doi: 10.1128/JVI.01579-17. Print 2017 Dec 1.
8
Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.一种H5N1疫苗在人体内诱导产生广泛反应性抗血凝素茎部抗体
J Virol. 2014 Nov;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep 10.
9
Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.基于嵌合血凝素的流感病毒疫苗接种在人体内诱导的抗体赋予 FcγR 依赖性的体内保护作用。
Proc Natl Acad Sci U S A. 2023 Oct 31;120(44):e2314905120. doi: 10.1073/pnas.2314905120. Epub 2023 Oct 23.
10
Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice.用表达 NP、M1 和嵌合血凝素的病毒载体进行免疫接种可诱导小鼠对流感病毒攻击产生广泛的保护作用。
Vaccine. 2019 Sep 3;37(37):5567-5577. doi: 10.1016/j.vaccine.2019.07.095. Epub 2019 Aug 6.

引用本文的文献

1
A clade 2.3.4.4b H5N1 virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins.一种2.3.4.4b分支H5N1病毒疫苗,可引发针对H5和N1糖蛋白保守结构域的交叉保护性抗体。
bioRxiv. 2025 Aug 14:2025.08.14.670375. doi: 10.1101/2025.08.14.670375.
2
Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model.基于多价H3 COBRA的流感疫苗在免疫前老年雪貂模型中引发增强的免疫反应。
Vaccine. 2025 May 22;56:127156. doi: 10.1016/j.vaccine.2025.127156. Epub 2025 Apr 22.
3
Immunological drivers of zoonotic virus emergence, evolution, and endemicity.

本文引用的文献

1
Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses.基于灭活裂解嵌合和镶嵌血凝素病毒的通用流感疫苗的生物工艺开发。
Front Bioeng Biotechnol. 2023 Jun 5;11:1097349. doi: 10.3389/fbioe.2023.1097349. eCollection 2023.
2
Commercial influenza vaccines vary in HA-complex structure and in induction of cross-reactive HA antibodies.商业流感疫苗在 HA 复合物结构和诱导交叉反应性 HA 抗体方面存在差异。
Nat Commun. 2023 Mar 30;14(1):1763. doi: 10.1038/s41467-023-37162-z.
3
Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses.
人畜共患病毒出现、进化和地方性流行的免疫学驱动因素。
Immunity. 2025 Apr 8;58(4):784-796. doi: 10.1016/j.immuni.2025.03.014. Epub 2025 Mar 31.
4
Structural characterization of influenza group 1 chimeric hemagglutinins as broad vaccine immunogens.1型流感嵌合血凝素作为广谱疫苗免疫原的结构表征
Proc Natl Acad Sci U S A. 2025 Feb 18;122(7):e2416628122. doi: 10.1073/pnas.2416628122. Epub 2025 Feb 12.
5
Structural mapping of polyclonal IgG responses to HA after influenza virus vaccination or infection.流感病毒疫苗接种或感染后针对血凝素(HA)的多克隆IgG反应的结构图谱分析
mBio. 2025 Mar 12;16(3):e0203024. doi: 10.1128/mbio.02030-24. Epub 2025 Feb 6.
6
Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach.基于嵌合血凝素方法的通用乙型流感病毒灭活疫苗的临床前评估
NPJ Vaccines. 2024 Nov 17;9(1):222. doi: 10.1038/s41541-024-01014-8.
7
The potential of nano- and microparticle-based influenza vaccines with enhanced shelf lives.具有延长保质期的基于纳米和微粒的流感疫苗的潜力。
Nanomedicine (Lond). 2024;19(26):2135-2138. doi: 10.1080/17435889.2024.2392484. Epub 2024 Oct 8.
8
Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice.工程益生菌大肠杆菌在小鼠中引发针对甲型流感病毒的即时和长期保护。
Nat Commun. 2024 Aug 9;15(1):6802. doi: 10.1038/s41467-024-51182-3.
9
Structural Mapping of Polyclonal IgG Responses to HA After Influenza Virus Vaccination or Infection.流感病毒疫苗接种或感染后针对血凝素(HA)的多克隆IgG反应的结构图谱
bioRxiv. 2024 Jul 11:2024.07.08.601940. doi: 10.1101/2024.07.08.601940.
10
Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicits protective immune responses against influenza viruses.多聚 COBRA 血凝素与 cGAMP 微粒制剂诱导针对流感病毒的保护性免疫应答。
mSphere. 2024 Jul 30;9(7):e0016024. doi: 10.1128/msphere.00160-24. Epub 2024 Jun 26.
与血凝素茎免疫原共同免疫可引发跨组别的中和抗体,并对甲型流感病毒提供广泛保护。
Immunity. 2022 Dec 13;55(12):2405-2418.e7. doi: 10.1016/j.immuni.2022.10.015. Epub 2022 Nov 9.
4
An epitope-enriched immunogen expands responses to a conserved viral site.一种富含表位的免疫原可增强对保守病毒位点的反应。
Cell Rep. 2022 Nov 8;41(6):111628. doi: 10.1016/j.celrep.2022.111628.
5
Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses.评估一种针对 2 型流感病毒的四价核苷修饰 mRNA 疫苗。
Proc Natl Acad Sci U S A. 2022 Nov 8;119(45):e2206333119. doi: 10.1073/pnas.2206333119. Epub 2022 Nov 2.
6
Human infection of avian influenza A H3N8 virus and the viral origins: a descriptive study.人感染甲型流感 H3N8 病毒及病毒来源:描述性研究。
Lancet Microbe. 2022 Nov;3(11):e824-e834. doi: 10.1016/S2666-5247(22)00192-6. Epub 2022 Sep 14.
7
An In Vitro Microneutralization Assay for Influenza Virus Serology.流感病毒血清学的体外微量中和试验。
Curr Protoc. 2022 Jul;2(7):e465. doi: 10.1002/cpz1.465.
8
Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface.与茎和三聚体界面具有广泛保护作用的抗体复合的流感嵌合血凝素结构。
Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200821119. doi: 10.1073/pnas.2200821119. Epub 2022 May 20.
9
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.嵌合血凝素流感裂解疫苗与 AS01 或 AS03 佐剂或无佐剂联合使用的反应原性、安全性和免疫原性:一项 1-2 期随机对照试验。
Lancet Infect Dis. 2022 Jul;22(7):1062-1075. doi: 10.1016/S1473-3099(22)00024-X. Epub 2022 Apr 21.
10
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.单剂量腺病毒疫苗为小鼠提供血凝素茎介导的针对异型流感病毒挑战的保护。
Mol Ther. 2022 May 4;30(5):2024-2047. doi: 10.1016/j.ymthe.2022.01.011. Epub 2022 Jan 7.